Tezosentan

Tezosentan is a non-selective ET_A and ET_B receptor antagonist.^[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.^[2]

Additional recommended knowledge

Daily Sensitivity Test

Guide to balance cleaning: 8 simple steps

What is the Correct Way to Check Repeatability in Balances?

References

1. ^ Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut 53: 1844-1849. “publisher= BMJ Publishing Group Ltd & British Society of Gastroenterology”
2. ^ Tezosentan does not appear to improve symptoms for patients with acute heart failure. Medical Studies/Trials. news-medical.net (7-Nov-2007). Retrieved on 2007-11-24.